The company was founded in 2002 and is an innovative pharmaceutical enterprise integrating R&D, production and sales of pharmaceutical preparations and APIs. The company was successfully listed on the main board of the Shenzhen Stock Exchange on December 15, 2020. The company's main business includes the pharmaceutical industry and pharmaceutical business. The company's main products are felodipine extended-release tablets, doxazosin mesylate extended-release tablets, nifedipine controlled-release tablets, trimetazidine hydrochloride sustained-release tablets, ketone capsules, oxycodone hydrochloride sustained-release tablets, venlafaxine hydrochloride sustained-release tablets, yqi and stomach capsules, phedrone oral solution, Jin Zhen eye drops, gatifloxacin eye drops, pyrimidine potassium eye drops, dampicol ointment, kacnidone gel, quinine tablets Tablets, metformin glipizide tablets. Corporate honors: The company has obtained more than 30 invention patents, and has successively won honors such as “National Torch Program Key High-tech Enterprise”, “Anhui Province Innovative Enterprise”, “Provincial Certified Enterprise Technology Center”, “Anhui Pharmaceutical Industry's Most Valuable Investment Enterprise”, “Anhui Drug Retention Engineering Technology Center”, “Hefei Intellectual Property Demonstration Enterprise”, and “Anhui American Brand Demonstration Enterprise” for eight consecutive years.
No Data